What molecular testing should be performed on a newly diagnosed non‑small cell lung cancer patient (unresectable stage III or stage IV) prior to systemic therapy?

Molecular Testing for Newly Diagnosed Unresectable Stage III or Stage IV NSCLC

All patients with newly diagnosed unresectable stage III or stage IV NSCLC should undergo comprehensive molecular testing with a broad multi-gene next-generation sequencing (NGS) panel on tissue and/or blood, plus PD-L1 immunohistochemistry (IHC), performed immediately at diagnosis before initiating any systemic therapy 1.

Essential Biomarkers to Test

The following driver alterations must be assessed as they directly determine first-line treatment selection:

Tier 1 - Highest Priority Alterations

• EGFR mutations (exon 19 deletions, exon 21 L858R, exon 20 insertions, T790M)
• ALK rearrangements (EML4-ALK and others)
• ROS1 rearrangements (CD74-ROS1 and others)
• BRAF V600E mutations
• MET exon 14 skipping mutations
• RET rearrangements (KIF5B-RET and others)
• NTRK rearrangements (ETV6-NTRK and others)
• PD-L1 expression (via IHC assay)

Additional Recommended Markers

• HER2 (ERBB2) mutations, amplifications, and overexpression
• KRAS mutations (particularly G12C)
• MET amplification

1, 2

Testing Methodology

Use broad multi-gene NGS panels as the preferred approach rather than sequential single-gene testing, as this:

• Detects multiple alterations simultaneously
• Preserves limited tissue
• Reduces turnaround time
• Identifies co-occurring mutations that may affect treatment decisions

1

Tissue vs. Liquid Biopsy Strategy

Attempt tissue testing first when feasible, as it provides:

• Histologic assessment capability
• Higher sensitivity for certain alterations
• Definitive diagnosis

Add liquid biopsy (blood-based ctDNA testing) when:

• Tissue quantity is insufficient
• Tissue biopsy is not feasible or safe
• Rapid results are needed to expedite treatment
• Combined testing maximizes detection rates

1

Critical caveat: Liquid biopsy has a false-negative rate—if negative, do not rule out driver alterations. The combination of tissue and blood testing maximizes the chance of detecting molecular alterations 1.

Timing Considerations

Order molecular testing immediately when advanced NSCLC with adenocarcinoma component is suspected—ideally by the pulmonologist, interventional radiologist, or thoracic surgeon at the time of biopsy, not waiting for oncology referral 3. This prevents treatment delays that commonly occur in real-world practice.

Do not use PD-L1 IHC alone to guide treatment decisions—comprehensive molecular profiling must be completed first, as the presence of driver alterations fundamentally changes the treatment algorithm away from immunotherapy 1.

Common Pitfalls to Avoid

1. Starting chemotherapy or immunotherapy before molecular results return: This is inappropriate for patients with actionable mutations who should receive targeted therapy first-line
2. Testing only for EGFR and ALK: This misses 15-20% of patients with other actionable alterations
3. Assuming liquid biopsy negativity rules out mutations: Always consider tissue testing if liquid biopsy is negative
4. Delaying testing until after initial treatment: Molecular testing should occur at diagnosis, not after first-line failure

1, 3

Special Considerations

For patients with poor performance status, molecular testing remains essential as targeted therapies often have better tolerability profiles than chemotherapy and may be preferentially offered based on drug access and toxicity considerations 1.

Pathologist-directed reflex testing (automatic initiation of molecular testing upon diagnosis) represents best practice and should be implemented institutionally to ensure universal access and eliminate delays 1, 3.